Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.

scientific article published in March 2015

Phase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1097/JTO.0000000000000434
P698PubMed publication ID25695221

P50authorMitsune TanimotoQ71779893
Katsuyuki KiuraQ71792097
Katsuyuki HottaQ91655587
Daijiro HaradaQ92778370
Eiki IchiharaQ97549768
Nagio TakigawaQ97688488
Toshiyuki KozukiQ98171027
Hiroshi UeokaQ114418730
Akihiro BesshoQ114418738
Naoyuki NogamiQ114418753
Keisuke AoeQ114418763
Shoichi KuyamaQ114418774
Kenichi ChikamoriQ114418775
Daizo KishinoQ114418776
Shinobu HosokawaQ114418779
Toshio KuboQ114418780
Akiko Hisamoto-SatoQ114418845
P2093author name stringMasahiro Tabata
Isao Oze
Masanori Fujii
P433issue3
P921main subjectlung cancerQ47912
bevacizumabQ413299
phase II clinical trialQ42824440
P304page(s)486-491
P577publication date2015-03-01
P1433published inJournal of Thoracic OncologyQ2448056
P1476titlePhase II trial of gefitinib in combination with bevacizumab as first-line therapy for advanced non-small cell lung cancer with activating EGFR gene mutations: the Okayama Lung Cancer Study Group Trial 1001.
P478volume10

Reverse relations

cites work (P2860)
Q33685254A prospective cohort study of patients with non-squamous non-small cell lung cancer treated with bevacizumab
Q41895086Addition of bevacizumab for malignant pleural effusion as the manifestation of acquired EGFR-TKI resistance in NSCLC patients
Q91328931Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)
Q54124211Amino acid starvation culture condition sensitizes EGFR-expressing cancer cell lines to gefitinib-mediated cytotoxicity by inducing atypical necroptosis.
Q38525073An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer
Q42673264Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
Q37688567Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation
Q50345931Combination Strategies Using EGFR-TKi in NSCLC Therapy: Learning from the Gap between Pre-Clinical Results and Clinical Outcomes
Q33914234Combination therapy in combating cancer
Q58116134Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model
Q40562646EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
Q97885844Efficacy and Safety of Epidermal Growth Factor Receptor (EGFR) Inhibitors Plus Antiangiogenic Agents as First-Line Treatments for Patients With Advanced EGFR-Mutated Non-small Cell Lung Cancer: A Meta-Analysis
Q39556310Efficacy of multimodal treatment for leptomeningeal metastases in a lung cancer harboring an EGFR mutation
Q90357265Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non-T790M mutations after progression on first-line EGFR-tyrosine kinase inhibitors
Q38729111ErbB Family Signalling: A Paradigm for Oncogene Addiction and Personalized Oncology
Q40251565Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial
Q60921601First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive Mutation-Positive Non-Small Cell Lung Cancer?
Q55370438Gastrointestinal perforation during treatment with erlotinib plus bevacizumab in two patients with non-small cell lung cancer exhibiting epidermal growth factor receptor mutations: A case report.
Q26744339Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
Q99238415KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
Q50146512Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors.
Q55327976Neoplastic meningitis in solid tumors: from diagnosis to personalized treatments.
Q89741649New advances in antiangiogenic combination therapeutic strategies for advanced non-small cell lung cancer
Q52668159Newly developed anti-angiogenic therapy in non-small cell lung cancer
Q36750945Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis.
Q64235237Prognostic impact of pleural effusion in EGFR-mutant non-small cell lung cancer patients without brain metastasis
Q26768125Pulmonary Toxicities of Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of Randomized Controlled Trials
Q55507456Real world study of regimen containing bevacizumab as first-line therapy in Chinese patients with advanced non-small cell lung cancer.
Q57460541Real world study of the continuation of bevacizumab beyond disease progression after first-line treatment containing bevacizumab in Chinese patients with advanced non-small cell lung cancer
Q55191884Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
Q41593429Strategies targeting angiogenesis in advanced non-small cell lung cancer
Q49894049Targeted therapy for leptomeningeal metastases in non-small cell lung cancer - Changing treatment paradigms
Q52726981Targeting the metastatic niche through anti-angiogenic approaches in epidermal growth factor receptor mutant non-small cell lung cancer
Q37698613Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.
Q33787355Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo
Q28075291Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options

Search more.